Drug Trial Radar · NCT05987449
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A
Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Sep 21, 2023
Primary completion
Dec 11, 2033
Study completion Dec 11, 2033
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Aug 14, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 2 years, up to 59 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
WP44714 is a Phase I/II, open-label, non-randomized, global, multicenter trial consisting of two parts: * Part 1 is a multiple-ascending dose (MAD) study in adult and adolescent male participants with severe or moderate hemophilia A with or without factor VIII (FVIII) inhibitors. * Part 2 is a multiple-dose study in pediatric male participants with severe or moderate hemophilia A with or without FVIII inhibitors. The overall aim of the study is to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of NXT007.
Conditions
- Hemophilia A
Interventions
NXT007Drug
Participants will receive NXT007 administered subcutaneously (SC), 2 loading doses once every two weeks (Q2W) followed by once every 4 weeks (Q4W) maintenance doses based on the schedule.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and Severity of Adverse Events, with Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events Grading ScaleTime frame: From Baseline until study completion or discontinuation (up to 7.5 years)
- Number of Participants with at Least One Clinical Laboratory Test Abnormality for Hematology ParametersTime frame: From Baseline until study completion or discontinuation (up to 7.5 years)
- Number of Participants with at Least One Clinical Laboratory Test Abnormality for Blood Chemistry ParametersTime frame: From Baseline until study completion or discontinuation (up to 7.5 years)
- Number of Participants with at Least One Vital Sign AbnormalityTime frame: From Baseline until study completion or discontinuation (up to 7.5 years)
- Number of Participants with at Least One Abnormality on Electrocardiogram (ECG) RecordingsTime frame: From Baseline until study completion or discontinuation (up to 7.5 years)
Locations
14 sites in 6 countries. Site status is shown where the registry gives one.
UC Davis Cancer Center
Sacramento, California · Recruiting
Georgetown Uni Medical Center
Washington D.C., District of Columbia · Withdrawn
Indiana Hemophilia & Thrombosis center
Indianapolis, Indiana · Recruiting
University of Iowa Hospitals and Clnics Dept of Pediatrics
Iowa City, Iowa · Recruiting
British Columbia Children's Hospital
Vancouver, British Columbia, Canada · Recruiting
Hamilton Health Sciences Corporation
Hamilton, Ontario, Canada · Recruiting
IRCCS Ca' Granda Ospedale Maggiore Policlinico
Milan, Lombardy, Italy · Recruiting
Istituto Clinico Humanitas
Rozzano (MI), Lombardy, Italy · Recruiting
Auckland Cancer Trial Centre
Auckland, New Zealand · Recruiting
Uniwersyteckie Centrum Kliniczne
Gda?sk, Poland · Recruiting
Instytut Hematologii i Transfuzjologii
Warsaw, Poland · Recruiting
Hospital Universitario la Paz
Madrid, Spain · Recruiting
Hospital Regional Universitario Carlos Haya
Málaga, Spain · Active not recruiting
Hospital Sant Joan de Deu
Esplugues de Llobregat, Barcelona, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.